Bufuralol
From Wikipedia, the free encyclopedia
 |
|
| Names | |
|---|---|
| IUPAC name
2-(tert-Butylamino)-1-(7-ethyl-1-benzofuran-2-yl)ethanol
|
|
| Identifiers | |
54340-62-4  |
|
| ChEMBL | ChEMBL296035 |
| ChemSpider | 64777 |
| Jmol 3D model | Interactive image |
| PubChem | 71733 |
| UNII | 891H89GFT4 |
|
|
|
|
| Properties | |
| C16H23NO2 | |
| Molar mass | 261.37 g·mol−1 |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
| Infobox references | |
Bufuralol is a potent beta-adrenoceptor antagonist with partial agonist activity.[1] It is metabolized by CYP2D6.[2]
Mostly all of the beta-blockers are aryloxypropanolamine based. In this rare exception, the benzofuran oxygen is part of a ring instead of derived from the epichlorohydrin precursor. iN this way , it could be considered a surrogate.
References[edit]
- ^ Pringle, TH; Francis, RJ; East, PB; Shanks, RG (1986). "Pharmacodynamic and pharmacokinetic studies on bufuralol in man". British Journal of Clinical Pharmacology 22 (5): 527–34. doi:10.1111/j.1365-2125.1986.tb02931.x. PMC 1401192. PMID 2878678.
- ^ Flockhart DA (2007). "Drug Interactions: Cytochrome P450 Drug Interaction Table". Indiana University School of Medicine. Retrieved on July 2011
 |
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
